Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Other Non-Current Liabilities (2016 - 2024)

Oramed Pharmaceuticals filings provide 14 years of Other Non-Current Liabilities readings, the most recent being $60000.0 for Q4 2024.

  • Quarterly Other Non-Current Liabilities fell 4.76% to $60000.0 in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $60000.0 through Dec 2024, down 4.76% year-over-year, with the annual reading at $60000.0 for FY2024, 4.76% down from the prior year.
  • Other Non-Current Liabilities hit $60000.0 in Q4 2024 for Oramed Pharmaceuticals, roughly flat from $60000.0 in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $1.0 million in Q3 2020 and bottomed at $11000.0 in Q1 2020.
  • Average Other Non-Current Liabilities over 5 years is $123650.0, with a median of $61000.0 recorded in 2022.
  • Peak annual rise in Other Non-Current Liabilities hit 9281.82% in 2020, while the deepest fall reached 96.41% in 2020.
  • Oramed Pharmaceuticals' Other Non-Current Liabilities stood at $212000.0 in 2020, then tumbled by 42.45% to $122000.0 in 2021, then tumbled by 50.0% to $61000.0 in 2022, then rose by 3.28% to $63000.0 in 2023, then dropped by 4.76% to $60000.0 in 2024.
  • Per Business Quant, the three most recent readings for ORMP's Other Non-Current Liabilities are $60000.0 (Q4 2024), $60000.0 (Q3 2024), and $60000.0 (Q2 2024).